Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer

Submitted by admin on August 16, 2022 - 11:17am
Source: 
Endpoints
News Tags: 
Roche
Polivy
diffuse large B-cell lymphoma
FDA
Headline: 
Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer
snippet: 

While Roche has previously touted Polivy data for diffuse large B-cell lymphoma (DLBCL), the drug has faced some delays on the regulatory side. But the most recent news from the FDA looks encouraging for the biotech.

Do Not Allow Advertisers to Use My Personal information